Immunity Pharma Ltd. (IPL) develops therapies for neuro-degenerative diseases with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. While there is currently no cure for ALS, there is massive market potential for an ALS therapy.
IPL’s lead drug, IPL344, originates from the research laboratory of Prof. Irun Cohen at the Weizmann Institute of Science, Israel.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.